首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 187 毫秒
1.
目的探讨子宫肌瘤子宫动脉栓塞治疗与子宫肌瘤剔除术治疗疗效.方法回顾分析40例(A组)经子宫动脉栓塞治疗、42例(B组)经腹腔镜子宫肌瘤剔除术、36例(C组)经阴式子宫肌瘤剔除术及30例(D组)经腹式子宫肌瘤剔除术治疗子宫肌瘤病例临床资料及随访情况,分析疗效.结果4组病例均保留子宫,临床症状均明显改善,且未出现明显并发症.术后随访3~24 个月(平均18个月),术后6个月,A组子宫及肌瘤体积缩小平均62%,6例肌瘤消失;B、C、D组子宫体积缩小平均84%.术后18个月,A组子宫及肌瘤体积缩小平均86%,子宫体积恢复正常大小23例,14例肌瘤消失,B、C、D组子宫体积恢复正常大小分别为30例、29例、23例,肌瘤复发分别为3例、2例、2例.结论子宫动脉栓塞治疗与子宫肌瘤剔除术治疗子宫肌瘤均有良好疗效,子宫肌瘤剔除术治疗子宫肌瘤后子宫体积恢复正常大小及肌瘤消失率较子宫动脉栓塞治疗法高,但近期复发率高于子宫动脉栓塞治疗法.  相似文献   

2.
目的:评价子宫动脉栓塞治疗子宫肌瘤的远期疗效.方法:子宫动脉栓塞治疗子宫肌瘤并接受术后完整随访3年以上的患者共45例,随访子宫肌瘤变化和症状缓解情况、卵巢功能和术后生命质量.结果:治疗后3例子宫粘膜下肌瘤和5例直径小于3.0 cm的肌壁间肌瘤消失,3例无效,45例肌瘤体积平均缩小65%,未发现肌瘤复发,临床症状减轻或完全消失;除3例闭经外的42例治疗前后激素水平差异无统计学意义;治疗后6月生命质量初步改善,7~12月显著改善,12月以后处于稳定期.结论:子宫动脉栓塞治疗子宫肌瘤能使肌瘤体积明显缩小并缓解症状,对40岁以下患者的卵巢功能无明显影响,术后生命质量提高.  相似文献   

3.
目的 :评价聚乙烯乙醇 (polyvinylalcohol,PVA)与真丝线段栓塞子宫动脉治疗子宫肌瘤的临床疗效及副反应。方法 :50例子宫肌瘤患者随机分为PVA与真丝线段栓塞两组。采用Seldinger方法经皮股动脉穿刺 ,血管造影确认子宫动脉及肌瘤所在部位后 ,超选择性子宫动脉插管并经导管注入PVA颗粒或真丝线段 ,阻断子宫肌瘤血供。治疗前后均用B超测量子宫肌瘤体积。结果 :两组患者月经量恢复正常和明显减少 ,总有效率为 97.73% ;术后 3个月和6个月肌瘤体积较治疗前缩小 4 5.81%和 51.80 % ,差异有高度显著性 (P <0 .0 1)。两组月经量和子宫肌瘤体积变化差异无显著性。两组的主要副反应是术后缺血性盆腔疼痛。术后发热症状 ,真丝线段组明显高于PVA组 (P <0 .0 5) ,无严重并发症发生。结论 :使用PVA或真丝线段超选择性子宫动脉栓塞治疗子宫肌瘤创伤小 ,近期临床疗效好 ,远期疗效有待进一步观察  相似文献   

4.
瘤内注射无水乙醇治疗子宫肌瘤的临床研究   总被引:7,自引:0,他引:7  
目的观察彩色多普勒超声引导下经皮瘤内注射无水乙醇(PEIT)治疗子宫肌瘤的疗效。方法对79例子宫肌瘤患者采用超声引导下PEIT治疗,术后3个月、6个月、12个月分别观察肌瘤体积、内部血流及临床症状改善情况。结果PEIT后3个月、6个月、12个月子宫体积和肌瘤体积分别缩小为50.2%、64.3%、67.6%和52.9%、71.9%、73.4%。彩色多普勒血流显示肌瘤内部及周边血流明显减少,月经量明显减少,贫血症状显著改善。结论PEIT治疗子宫肌瘤操作简便、安全有效。  相似文献   

5.
子宫动脉栓塞治疗子宫肌瘤的疗效和并发症分析   总被引:10,自引:0,他引:10  
目的 探讨选择性子宫动脉栓塞治疗子宫肌瘤的临床疗效和并发症的发生情况。方法  2 0 0 0年 10月~ 2 0 0 2年 5月选择 4 0例子宫肌瘤患者用PVA颗粒做栓塞剂行子宫动脉栓塞 ,栓塞后定期评价临床疗效和并发症 ,彩超监测子宫和最大肌瘤体积。根据SCVIR制订的并发症分级系统 ,评价并发症的严重性。结果 4 0例患者行子宫动脉栓塞 ,平均随访 18 9个月 ,97%临床症状改善。子宫和最大肌瘤体积平均缩小 4 3 8%和6 3 5 %。栓塞前子宫和最大肌瘤体积的中位数为 2 4 3 4cm3和 14 8cm3,栓塞后 6个月中位数为 10 7 1cm3和4 1 1cm3,(P <0 0 0 1)。 88 5 %的并发症为A、B级 ,1例 (2 5 % )D级并发症为阴道排瘤继发感染再入院治疗。7例 (17 5 % )较严重的栓塞后综合征。 1例 (2 5 % ) 2年后复发。 4例 (10 0 % )卵巢功能衰竭 ,发生在栓塞后2~ 18个月。 2 0例 (5 0 0 % )患者阴道排液。 92 5 %患者对治疗的结局表示满意。结论 子宫动脉栓塞治疗子宫肌瘤能有效的改善症状 ,缩小瘤体 ,失败率低 ,严重并发症少。术前严格选择适应症 ,术后预防感染是降低并发症的关键。  相似文献   

6.
超声引导下瘤内无水乙醇注射治疗子宫肌瘤的初步研究   总被引:27,自引:1,他引:26  
目的 观察超声引导下经皮无水乙醇注射 (PEIT)治疗子宫肌瘤的疗效。方法 对 2 5例子宫肌瘤患者采用超声引导下PEIT治疗。 10例行PEIT 5天后手术切除肌瘤 ,观察肌瘤内坏死情况 ;15例在行PEIT后定期观察肌瘤体积及内部血流变化。结果  10例手术组 5例注射无水乙醇 3ml者 ,肌瘤中央坏死范围直径约 2cm ,另 5例注射 5ml者 ,坏死范围直径约 3cm ;未手术组注射治疗前平均肌瘤体积 10 5 5cm3 ,2个月后缩小为 74 6cm3(P <0 0 1) ;6个月后体积未再增大 (6 2 4cm3 ,P >0 0 5 ) ,彩超显示肌瘤内部及周边血流明显减少。结论 PEIT治疗子宫肌瘤灭瘤效果确实 ,近期疗效满意 ,有关远期疗效及剂量与效果的关系正进行深入研究。  相似文献   

7.
射频消融术靶位治疗子宫肌瘤临床疗效研究   总被引:15,自引:0,他引:15  
目的 探讨射频消融术靶位治疗子宫肌瘤的临床疗效.方法 选择暨南大学附属第一医院、武汉大学人民医院和陨阳医学院十堰市太和医院妇产科2001年8月至2006年12月经临床和超声检查确诊为子宫肌瘤的260例患者,在超声监视和引导下经阴道进行射频消融治疗,于术后第1、3、6和12个月随访.其中56例于治疗前和治疗后6个月同时行盆腔彩超检查子宫和卵巢血流的改变,放射免疫法检测卵巢和垂体激素水平变化.结果 治疗后6个月72.67%月经恢复正常,64.71%痛经消失,64.81%下腹不适和膀胱、直肠压迫症状均消失.治疗后12个月82.56%患者月经恢复正常,74.51%痛经消失,72.22%下腹不适和膀胱、直肠压迫症状均消失.射频消融治疗术后子宫及其肌瘤体积呈进行性缩小,治疗术后6个月和12个月肌瘤体积缩小率为69.56%和76.38%,子宫体积缩小率为42.29%和46.27%.术后6个月和12个月总有效率分别为95.38%和97.69%.子宫肌瘤患者子宫动脉血液供应比健康妇女丰富(P<0.05),治疗后明显降低,与健康妇女无明显差别.卵巢动脉血液供应、卵巢性激素、垂体促性腺激素水平治疗后与治疗前无明显变化,与健康妇女比较差异无显著性意义(P>0.05).全部治疗病例无严重并发症.结论 射频消融术靶位治疗子宫肌瘤临床疗效好,创伤小,安全性高.  相似文献   

8.
介入治疗在子宫肌瘤合并继发性贫血中的应用   总被引:6,自引:0,他引:6  
目的 研究选择性子宫动脉栓塞术 (UAE)治疗在子宫肌瘤合并继发性贫血中的临床效果。方法 采用Seldingers方法作选择性子宫动脉栓塞 ,治疗 4 5例合并继发性贫血的子宫肌瘤患者。结果 随访 18~ 2 4个月。血红蛋白值 (Hb)由术前的 (84 4± 2 1 6 ) g/L恢复至 (12 0 6± 13 1)g/L。月经周期无改变 ,经期缩短 ,月经量减少至术前的 (5 0 6± 18 2 ) %。子宫及肌瘤体积均有不同程度的缩小。结论 UAE治疗子宫肌瘤合并继发性贫血患者 ,能有效地减少月经量 ,缩小瘤体 ,迅速纠正贫血 ,疗效肯定  相似文献   

9.
射频热凝固微创技术治疗子宫良性病变的初步研究   总被引:39,自引:0,他引:39  
目的 :探讨射频热凝固微创治疗子宫肌瘤、腺肌瘤和功能失调性子宫出血(功血 )等子宫良性病变的临床特点和疗效。方法 :在B超监测下 ,应用凝固器 ,将射频定点介入到子宫病灶内使局部温度达 5 5℃~ 85℃ ,使病变组织热凝固坏死吸收 ,治疗各类直径小于 5 .0cm的子宫肌瘤 2 2 2例、腺肌瘤 10 4例、功血 5 1例、II度和III度子宫颈糜烂 60例和 5 3例。结果 :经 35~ 4 5W射频治疗 2~ 11min ,2~ 3月后病灶直径均不同程度的缩小 ,用本法治疗子宫肌瘤有效率为 94 .6% ,腺肌瘤为 87.5 % ,功血为 94 .1% ,宫颈糜烂为 10 0 .0 %。结论 :射频热凝固治疗子宫肌瘤 (<5 .0cm)、腺肌瘤、功血和宫颈糜烂时间短 ,见效快 ,疗效高 ,患者住院时间短 ,治疗费用低  相似文献   

10.
目的:探讨子宫腺肌病(AM)患者放置左炔诺孕酮宫内缓释系统(LNG-IUS)后的中远期临床效果。方法:对48例AM患者放置LNG-IUS,记录放置前1个月、放置后第1年、第1.5年、第3年、第5年的痛经、月经量、子宫内膜厚度变化,同时阴道超声测量子宫大小及双侧卵巢体积等各项指标。放置LNG-IUS第1年、第1.5年及第3年、第5年抽取晨血查生殖内分泌激素水平及肝肾功能。结果:放置LNG-IUS后至少完成1年随访43例,随访率89.58%,平均随访50个月。43例患者术后痛经改善,临床有效率83.72%,与置LNG-IUS前比较,有统计学差异(P<0.01);子宫体积放置后1.5年与放置前比明显缩小(P<0.05);第3年、第5年缩小更明显(P<0.01)。放置后子宫内膜厚度明显变薄(P<0.01);生殖激素无明显变化。结论:LNG-IUS用于治疗子宫腺肌病具有较好的中远期效果。  相似文献   

11.
Liu X  Zhang X 《中华妇产科杂志》2000,35(12):730-732
OBJECTIVE: To investigate the biologic manner of intravenous uterine myoma and the clinical management. METHODS: Analysed 11 cases of intravenous leiomyoma retrospectively from 1994 to 1998, of which all specimens of intravenous leiomyoma were confirmed by pathologic examination. The estrogen receptor was measured by immunohistochemistry. RESULTS: Nine patients (81.8%) presented menorrhagia, two patients (18.2%) appeared anemia. The size of uterus more than three pregnancy months was seen in seven cases (63.6%), of which six patients (6/7) showed uterine multiple nodule and abundant blood flow by ultrasound compared with those whose uterine size smaller than three pregnancy months (P > 0.05). The correct diagnosis before operation was 0 percent, 63.6% of the patients was diagnosed during operation (P < 0.05). Seven patients (63.6%) had classical pathological appearance of intravenous leiomyoma. Positive estrogen receptors were detected in six patients. One patient (9.1%) was recurred. CONCLUSIONS: Uterine intravenous leiomyoma has typical clinical and pathologic feature. The adverse biologic manner and the clinical treatment are related to prognosis.  相似文献   

12.
血清及腹腔液CA125测定对子宫腺肌病的诊断价值   总被引:1,自引:0,他引:1  
目的探讨血清及腹腔液CA125测定对子宫腺肌病的诊断价值.方法采用免疫化学发光法测定28例子宫腺肌病和25例子宫肌瘤患者血清及腹腔液(110稀释)CA125水平.结果子宫腺肌病患者血清CA125水平高于子宫肌瘤患者,差异有显著性(P<0.01).两组间腹腔液CA125水平差异无显著性(P=0.18).腹腔液CA125水平明显高于血清CA125水平(P<0.01),但二者无明显相关性(P>0.50).腺肌病患者血清CA125水平受子宫大小、大体病理类型、使用性激素等因素影响.结论如用于子宫腺肌病的辅助诊断,血清CA125测定较腹腔液CA125测定敏感.腹腔液中CA125的主要来源可能为腹膜上皮细胞.  相似文献   

13.
OBJECTIVE: To assess maximal volume reduction of leiomyomas and uterus and the duration of treatment required to reach these reductions with daily GnRH antagonist treatment. DESIGN: Prospective, open-label study. SETTING: Large teaching hospital in The Netherlands. POPULATION: Premenopausal women with symptomatic fibroids, who were scheduled for surgery. METHODS: Twenty women were treated with daily 2 mg of subcutaneous ganirelix. Prior to the first injection and weekly during treatment, the volume of leiomyomas and the uterus were assessed by ultrasound (USS) and serum hormones were measured. Prior to treatment and when maximal size reduction was observed by USS, the volume of the leiomyomas and the uterus were also assessed by magnetic resonance imaging (MRI). MAIN OUTCOME MEASURES: Leiomyoma and uterine size reduction, time to maximal reduction. RESULTS: One woman was excluded from the study due to incorrect administration dose of ganirelix. Data on the remaining 19 women (average age 39 years) with subserosal (n= 9), submucosal (n= 7), intramural (n= 10) and transmural (n= 1) leiomyomas were evaluated. Baseline leiomyoma volumes ranged from small (3-4 mL) to large (>1000 mL). The median duration of treatment up to maximal leiomyoma size reduction was 19 days (range 1-65 days). The maximal size reduction in leiomyomas measured by USS was -42.7% (-77.0% to 14.1%) and -29.2% (-62.2% to 35.6%) by MRI. Comparable uterine size reductions of -46.6% (-78.6% to -6.1%) and -25.2% (-63.6% to 28.9%) were observed by USS and MRI. During the first three weeks of treatment, 8 out of 19 women reported adverse events related to the induced hypoestrogenic state. Most of these events resolved within one week after treatment was discontinued. CONCLUSION: Daily treatment with 2 mg of ganirelix results in rapid reduction of leiomyoma and uterine volume in premenopausal women with minor side effects. If longer-acting GnRH antagonists become available, pretreatment with GnRH antagonist should be preferred over GnRH agonists prior to surgery.  相似文献   

14.
目的观察促性腺激素释放激素类似物(曲普瑞林)治疗女童特发性中枢性性早熟(ICPP)的临床疗效。方法应用曲普瑞林治疗23例ICPP女童6个月,观察治疗前后第二性征、子宫、卵巢、骨龄(BA)、血清雌二醇(E2)、促性腺激素释放激素(GnRH)激发试验激素水平、预测成人终身高的变化及药物副反应。结果治疗后患儿乳房、子宫、卵巢体积均有缩小,E2、促黄体生成激素(LH)、卵泡刺激素(FSH)峰值均显著降低,骨龄成熟延迟,骨龄/实际生活年龄(BA/CA)值下降,预测成人终身高治疗前为(155.5±0.81)cm,治疗后为(157.0±0.81)cm,较治疗前有改善,差异具有统计学意义(P〈0.01)。结论曲普瑞林治疗ICPP能够抑制性腺轴及性腺发育,延缓BA成熟,最终对改善成人终身高有意义。  相似文献   

15.
目的:通过阴道超声评估来曲唑对多囊卵巢综合征(PCOS)的治疗作用。方法:来曲唑治疗38例PCOS患者,经阴道超声观察宫颈前后径、子宫内膜厚度和形态、优势卵泡个数,子宫动脉和卵巢基质血流PSV、EDV、PI、RI,与超声观察同天测定血清FSH、LH、E2、P,并与52例正常育龄妇女相比较。结果:来曲唑治疗PCOS有较高的排卵率(81.58%)和妊娠率(21.05%),并使子宫卵巢出现类似正常育龄妇女的周期性血流变化。结论:来曲唑改善了PCOS患者的子宫卵巢血流供应,利于妊娠。  相似文献   

16.
OBJECTIVE: To assess the effect of gonadotropin-releasing hormone (GnRH) agonist treatment upon angiogenesis in uterine leiomyomata. METHODS: Uterine leiomyomata specimens of 49 consecutive patients who underwent myomectomy or hysterectomy following presurgical treatment with (n = 23) and without (n = 26) GnRH agonist were stained immunohistochemically with antibody to factor VIII-related antigen. For each subject, age, parity, number of Lupron treatments, leiomyoma size (cm), and mean microvessel counts calculated from three fields (x400) were recorded. Differences in patient age, parity, microvessel counts and leiomyoma size between GnRH agonist treated and untreated patients were tested by unpaired Student's t test. Differences among the various number of doses were tested by one-way ANOVA, with Bonferonni and Neuman-Keuls post hoc tests between specific dose-number groups. The relationship between microvessel counts and leiomyoma size was tested by Pearson correlation test. Multivariate stepwise regression tested the relationship between the number of Lupron doses and microvessel counts, correcting for age, parity, and leiomyoma size. p < 0.05 was considered significant. RESULTS: Patient age and parity were similar in GnRH treated and untreated patients (mean 43.3 +/- 6.6 versus 43.9 +/- 7.5 years and median 2 (range 0-7) versus 1 (range 0-5), p = 0.78 and p = 0.45, respectively). Microvessel counts of leiomyomata specimens treated presurgically with GnRH agonist therapy (median 22.7, range 6.7-65.7) were not significantly different from microvessel counts of specimens without presurgical GnRH agonist treatment (median 19.8, range 6-53; p = 0.77). No correlation between leiomyoma size and microvessel counts was noted (r = 0.06, P = 0.7). CONCLUSION: Angiogenesis as assessed by microvessel counts in surgically removed leiomyomata is not affected by presurgical medical management with GnRH agonist therapy.  相似文献   

17.
458例变性及富细胞型子宫平滑肌瘤临床病理分析   总被引:2,自引:0,他引:2  
目的探讨不同组织学类型变性的子宫平滑肌瘤及富细胞型子宫平滑肌瘤的临床特点。方法回顾性分析北京大学第一医院1993年1月-2004年1月间收治的458例经手术后病理确诊为变性的子宫肌瘤患者的临床特点,并初步评价术前彩色多普勒超声和术中大体标本检查的诊断价值。结果①肌瘤良性变性常见的症状分别是肌瘤生长迅速31.47%(73,232),腹痛25.86%(60/232),月经量多或经期长24.57%(57,232);肌瘤肉瘤变时表现为肌瘤生长迅速66.67%(4,6);富细胞型平滑肌瘤常表现为月经量多或经期长31.36%(69/220),腹痛25.91(57/220),肌瘤生长迅速25%(55/220)。肌瘤生长迅速在肌瘤肉瘤变时尤为明显,与肌瘤良性变性和富细胞型平滑肌瘤比较有显著性区别(P<0.05);②肌瘤良性变性者中超声有提示者占25.43%(59/232),其中RI<0.4者占17.24%(10/232);富细胞子宫肌瘤中10.91%(24/220)和子宫肌瘤肉瘤变组33.33%(2/6)术前彩超提示RI<0.4。③富细胞型子宫肌瘤仅10.91%(24/220)手术时送冰冻切片检查,肌瘤肉瘤变的仅1,6例术中送冰冻检查。结论子宫肌瘤出现变性及富细胞型平滑肌瘤常表现为肌瘤生长迅速,在肌瘤肉瘤变时尤为明显,重视术前的彩色超声多普勒检查及术中仔细的大体标本检查有助于诊断。  相似文献   

18.
Liu DY  Gu MJ  Shu JZ  Shi YX  Wang CY  Han ZQ 《中华妇产科杂志》2006,41(10):656-659
目的探讨促性腺激素释放激素激动剂(GnRHa)在治疗子宫内膜异位症(内异症)、子宫腺肌病和子宫肌瘤中的作用以及延长用药间隔对疗效的影响。方法内异症、子宫腺肌病和子宫肌瘤患者共70例,随机分为两组即延长用药间隔组(E组,30例)与常规用药组(C组,40例),分别用曲普瑞林3·75mg肌内注射4次(间隔6周)或6次(间隔4周),疗程均为24周,比较用药前后症状、子宫体积和病灶体积、血清生殖激素水平变化。结果E、C两组中内异症和子宫腺肌病患者的痛经缓解率均为100%;药物治疗结束时子宫体积平均缩小35%和37%,治疗前后比较,差异有统计学意义(P<0·05)。两组患者药物治疗前后血清卵泡刺激素(FSH)、黄体生成素(LH)、雌二醇水平,E组从用药前的(6·7±1·4)U/L、(4·713±1·048)U/L、(209±29)pmol/L,下降到第1次用药后6周的(2·1±0·5)U/L、(0·496±0·212)U/L、(95±18)pmol/L,分别与用药前比较,差异均有统计学意义(P<0·05);用药前及第1次用药后12、24、28周,E、C两组分别比较,差异均无统计学意义(P>0·05)。结论GnRHa通过降低血清FSH、LH和雌二醇水平而缓解痛经、缩小病灶;大多数患者用药间隔延长至6周对疗效无影响,并且可降低医疗费用,可在有血清生殖激素监测条件下推荐应用。  相似文献   

19.
The purposes of this study were to investigate the effect of a superactive agonistic analog of gonadotropin-releasing hormone, nafarelin, on uterine leiomyomas and to assess the use of magnetic resonance imaging in monitoring uterine and myoma size. Eleven women with uterine leiomyomas were treated with 800 micrograms of nafarelin per day for 6 months. Serum gonadotropin and estradiol concentrations were suppressed during treatment. The mean +/- SEM serum luteinizing hormone level decreased from 11.1 +/- 1.4 to 5.6 +/- 0.42 mlU/ml and follicle-stimulating hormone from 9.5 +/- 0.66 to 7.5 +/- 0.72 mlU/ml by 3 months of treatment (p less than 0.01). The estradiol level decreased from a pretreatment follicular phase mean +/- SEM of 43 +/- 8.3 to 19.8 +/- 3.1 (p less than 0.05) and 14.8 +/- 2.2 pg/ml (p less than 0.01) at 3 and 6 months of treatment, respectively. Mean pretreatment androgen levels (testosterone, androstenedione, and dehydroepiandrosterone sulfate) were low in these women and did not change significantly during treatment. Ten women had magnetic resonance imaging, which provided excellent resolution of individual uterine myomas. As assessed by magnetic resonance imaging, the largest myoma decreased in size in nine of 10 women; the mean decrease was 46% +/- 9%. Uterine volume decreased in all 10 patients; the mean decrease was 57% +/- 7%. In several women myomas reenlarged after discontinuance of nafarelin treatment. Posttreatment myomectomy was carried out in four women; there was minimal blood loss and no surgical complications. These data indicate that suppression of ovarian estrogen production with nafarelin is associated with a decrease in uterine myoma size in many women but that myomas may regrow with reinstitution of ovarian function. Magnetic resonance imaging is an excellent method by which to monitor treatment as changes in the size of the uterus, as well as individual myomas, can be assessed. The optimal use of gonadotropin-releasing hormone analogs may be in perimenopausal women or as presurgical treatment to decrease uterine and myoma size to facilitate myomectomy.  相似文献   

20.
孙蕾  徐军 《现代妇产科进展》2006,15(12):918-920,923
目的:探讨子宫动脉栓塞术治疗症状性子宫肌瘤的中远期疗效。方法:对2000年1月至2004年12月上海市第八人民医院和上海市闸北区中心医院用子宫动脉栓塞术治疗的306例子宫肌瘤患者进行随访。结果:随访306例648个月,治愈42例(13.73%),显效207例(67.65%),有效40例(13.07%),无效17例(5.56%)。其中36例大于50岁的患者术后23个月出现闭经。224例患者术后性激素(E2、FSH、LH)值与治疗前无统计学差异(P>0.05)。结论:子宫动脉栓塞术是治疗症状性子宫肌瘤的又一种有效方法,中远期疗效确切,而且不影响其他治疗,术后可明显提高患者的生活质量。  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号